Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis

Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists

(2018) Hiroki Mitoma et al.   CYTOKINE

Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases

(2017) Jee Lee et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Infliximab crystal structures reveal insights into self-association

(2017) Thomas F. Lerch et al.   mAbs

Higher order structures of Adalimumab, Infliximab and their complexes with TNFα revealed by electron microscopy

(2017) Bich Ngoc Tran et al.   PROTEIN SCIENCE

Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases

(2016) Emma D. Deeks   BIODRUGS

Simple NMR methods for evaluating higher order structures of monoclonal antibody therapeutics with quinary structure

(2016) Kang Chen et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Effects of Protein Conformation, Apparent Solubility, and Protein–Protein Interactions on the Rates and Mechanisms of Aggregation for an IgG1Monoclonal Antibody

(2016) Cavan Kalonia et al.   JOURNAL OF PHYSICAL CHEMISTRY B

Acid-induced aggregation propensity of nivolumab is dependent on the Fc

(2016) Boning Liu et al.   mAbs

Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange

(2016) Karin A. van Schie et al.   Scientific Reports

State of the art paper Tumor necrosis factor inhibitors – state of knowledge

(2015) Krzysztof Lis et al.   Archives of Medical Science

Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol

(2014) Gianfranco Pasut   BIODRUGS

Intravenous golimumab in rheumatoid arthritis

(2014) Marc D Cohen et al.   Expert Review of Clinical Immunology

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α

(2014) David J. Shealy et al.   mAbs

Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?

(2013) Clara De Simone et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The Cytotoxic Effects of Certolizumab Pegol and Golimumab Mediated by Transmembrane Tumor Necrosis Factor α

(2013) Naoyasu Ueda et al.   INFLAMMATORY BOWEL DISEASES

Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View

(2013) Shi Hu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab

(2013) Shuaiyi Liang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Evidence that TNF-β (lymphotoxin α) can activate the inflammatory environment in human chondrocytes

(2013) Constanze Buhrmann et al.   ARTHRITIS RESEARCH & THERAPY

mTNF reverse signalling induced by TNFα antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease

(2012) Stefanie Derer et al.   GUT

Fc Gamma Receptor CD64 Modulates the Inhibitory Activity of Infliximab

(2012) Kacper A. Wojtal et al.   PLoS One

Origin and evolution of TNF and TNF receptor superfamilies

(2011) Gregory D. Wiens et al.   DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY

Update upon efficacy and safety of TNF-α inhibitors

(2011) Giuseppe Murdaca et al.   Expert Opinion On Drug Safety

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases

(2010) Peter C Taylor   CURRENT OPINION IN PHARMACOLOGY

Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts

(2010) Flavia Calmon-Hamaty et al.   CYTOKINE

Anti–Tumor Necrosis Factor-α Antibodies Induce Regulatory Macrophages in an Fc Region-Dependent Manner

(2010) Anne Christine W. Vos et al.   GASTROENTEROLOGY

Transmembrane TNF- : structure, function and interaction with anti-TNF agents

(2010) T. Horiuchi et al.   RHEUMATOLOGY

Solution of the Structure of the TNF-TNFR2 Complex

(2010) Y. Mukai et al.   Science Signaling

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

(2009) Zehra Kaymakcalan et al.   CLINICAL IMMUNOLOGY

Certolizumab pegol for the management of Crohn's disease in adults

(2009) Anastasia Rivkin   CLINICAL THERAPEUTICS

Differences in binding and effector functions between classes of TNF antagonists

(2009) Taruna Arora et al.   CYTOKINE

Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab

(2008) Hiroki Mitoma et al.   ARTHRITIS AND RHEUMATISM

A PEGylated Fab′ Fragment against Tumor Necrosis Factor for the Treatment of Crohn Disease

(2008) Tim Bourne et al.   BIODRUGS

Etanercept

(2008) Erin Ducharme et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS